FDA Requests Zantac Be Pulled From Shelves Over Cancer Concerns.

Contact us now to seek justice for a cancer diagnosis after Zantac

If you or a family member have been diagnosed with cancer after using Zantac, you may be able to take powerful legal action.

Contact us today for a free and confidential legal consult.

"*" indicates required fields

Email List
Want to stay in the know about important information to help protect your future? Simply subscribe to our newsletter!
This field is for validation purposes and should be left unchanged.

Zantac Pulled From Shelves Due to Cancer Concerns

In April 2020, the FDA called for the complete withdrawal of Zantac (aka ranitidine) from the market over concerns about the drug’s potential connection to cancer. This stronger stance comes several months after at least two manufacturers of Zantac issued a voluntary recall of the product after concerns about NDMA impurities. NDMA (or N-nitrosodimethylamine) is classified as a probable human carcinogen, according to the FDA. As a result, numerous retailers such as Walmart, CVS, and Walgreens pulled Zantac from shelves.

Zantac has been linked to multiple kinds of life-threatening cancers, including:

  • Bladder
  • Colorectal
  • Esophageal
  • Kidney
  • Liver
  • Lung
  • Intestinal
  • Ovarian
  • Pancreatic
  • Prostate

If you or a family member have been diagnosed with any of these cancers (or, sadly, if a family member has passed away from any of these cancers) after using Zantac, contact us immediately. You may have powerful legal options that could help others and possibly mean financial compensation for you and your family.

About That Recall.

In Apri 2020, the FDA requested all manufacturers pull Zantac from store shelves immediately after an ongoing investigation found that levels of the contaminant in the medication increase over time and when stored at higher temperatures.

In September 2019, the FDA announced a voluntary recall of certain lots of Zantac (also known as the generic Ranitidine) by manufacturer Sandoz for containing N-nitrosodimethylamine (NDMA), which is classified as a probable human carcinogen.

In November 2019, the recall was expanded to include additional lots of Zantac/Ranitidine manufactured by Amneal Pharmaceuticals LLC and Lannett Company. According to recall information from the FDA, the medication manufactured by Amneal Pharmaceutials contains unacceptable levels of NDMA. Most recently, Golden State Medical Supply, Inc. issued a voluntary nationwide recall of Ranitidine Hydrocholride 150mg and 300mg capsules manufactured by Novitium Pharma, LLC, adding to the growing list of recalled Ranitidine.

In response to the recall, numerous retailers, such as Walmart and Walgreens, have pulled Zantac from their shelves.

Contact Us

What Does This Mean for Lawsuits?

A lot, it turns out.

The first Zantac lawsuit was filed the very day that the FDA first issued its advisory about NDMA contamination concerns in Zantac. In the lawsuit, drug manufacturers Sanofi and Boerhringer Ingelheim were accused of manufacturing, marketing and selling a product they knew (or should have known) had been contaminated with a dangerous chemical that has been linked to cancer.

Keep in mind that this lawsuit does not cover every single Zantac case; each case filed by attorneys will be a separate case reviewed based on the specifics of each individual. These cases will not be part of a class action, rather they will be individual cases.

So much pain could have been prevented, but these pharmaceutical companies are more concerned with their profits than our safety. It’s time to demand accountability.

Learn how you can take legal action

NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests.”

-FDA Statement alerting patients and health care professionals of NDMA found in samples of ranitidine